MedTrace Logo

The Effect of an RBAC Supplement (BRM4) on NAFLD

NCT02568787 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-06-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD). This nutritional supplement is made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shiitake mushroom.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

rice bran arabinoxylan compound (RBAC)

Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.

DIETARY_SUPPLEMENT

Placebo

Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.

Sponsors & Collaborators

  • Daiwa Health Development

    collaborator OTHER

  • University of Miami

    lead OTHER

Principal Investigators

  • John E Lewis, Ph.D. · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-06-10
Completion
2017-06-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02568787 on ClinicalTrials.gov